Pulmonary arterial hypertension (PAH) is a progressive disease that despite advances in therapy is associated with a 7-year survival of approximately 50%. Several risk factors are associated with developing PAH, include methamphetamine use, scleroderma, human immunodeficiency virus, portal hypertension, and genetic predisposition. PAH can also be idiopathic. There are traditional pathways underlying the pathophysiology of PAH involving nitric oxide, prostacyclin, thromboxane A2, and endothelin-1, resulting in impaired vasodilation, enhanced vasoconstriction and proliferation in the pulmonary vasculature. Established PAH medications targets these pathways; however, this paper aims to discuss novel drugs for treating PAH by targeting new and alternative pathways.
Similar content being viewed by others
Pulmonary arterial hypertension (PAH) is a progressive disease with a high mortality rate despite advances in therapy.
Currently, therapies target traditional pathways such as nitric oxide, prostacyclin, thromboxane A2, and endothelin-1.
Several alternative pathways have been targeted in PAH patients and have shown to improve patient hemodynamics and functional class in patients with PAH.
Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure (mPAP) of > 20 mmHg by right heart catheterization. PH is classified into five separate groups: pulmonary arterial hypertension (PAH, Group1), PH due to left heart disease (PH-LHD, Group 2), PH due to lung disease (Group 3), PH due to obstruction of the pulmonary artery (Group 4), and PH due to multifactorial mechanism or unclear cause (Group 5) [Table 1] [1,2,3].
This article focuses on the pathophysiology and treatment of PAH. PAH is defined by an mPAP of > 20 mmHg, pulmonary capillary wedge pressure (PCWP) ⩽ 15, and pulmonary vascular resistance (PVR) ⩾ 2 Wood units. There are several subgroups of PAHs based on etiology: idiopathic PAH, which accounts for the majority of cases; heritable PAH, drug and toxin-induced PAH; and PAH associated with other conditions such as human immunodeficiency virus (HIV), portal hypertension, connective tissue disease, congenital heart disease and schistosomiasis (Table 1).
According to the current data, PAH is associated with a better prognosis compared with other forms of PH, primarily because of the PAH-specific treatment . The incidence of PAH is estimated to be up to 2.4 cases per million per year, whereas the prevalence is estimated to be up to 15 cases per million per year [5, 6]. However, despite the progress in treatment, the mortality rate remains high, with a 7-year survival rate of only 50%.
Age, sex, and underlying cause of PAH affect the prognosis. Higher mortality rates were reported in male patients with idiopathic and hereditary PAH, males over 60 years of age, patients with systemic sclerosis-associated PAH, portopulmonary hypertension, and patients with bone morphogenetic protein receptor 2 (BMPR2) mutation. Symptoms and functional class of the patients can also affect the outcomes based on some studies; however, exercise capacity with the 6-min walk test (6MWT) and cardiopulmonary exercise testing (CPET) can also help determine prognosis .
Regardless of the underlying etiology of PAH, the pathological features are similar and include endothelial dysfunction, endothelial and smooth muscle remodeling, and pulmonary artery smooth muscle cell proliferation. Multiple pathways are involved in the pathophysiology of PAH, including nitric oxide (NO), prostacyclin (PGI2), thromboxane A2 (TXA2), and endothelin-1 (ET-1) [5, 8, 9].
Endothelial cells produce NO, which diffuses to the underlying vascular smooth muscles, stimulating soluble guanylyl cyclase and increasing smooth muscle cyclic guanosine monophosphate (cGMP), resulting in pulmonary vasodilation. NO also inhibits smooth muscle cell proliferation and the aggregation of platelets. It is believed that there is a reduction in the bioavailability of NO in PAH, which was previously assumed to be caused by reduced expression of NO synthase (eNOS), which converts l-arginine to NO; however, recent studies have shown persistent eNOS activation in mice models of PAH. Consequently, reactive oxygen species (ROS), mainly tetrahydrobiopterin, have been implicated in endothelial dysfunction, vasoconstriction, and vascular remodeling due to enzymatic uncoupling of eNOS [5, 10, 11].
PGI2 is produced in endothelial cells from arachidonic acid, which increases smooth muscle cyclic adenosine monophosphate (cAMP), resulting in pulmonary vasodilation. In PAH, TXA2 may cause vasoconstriction and proliferation [5, 12].
ET-1 is a peptide produced by endothelial cells that causes vasoconstriction. ET-1 acts on two receptors; ETA is located in the pulmonary artery smooth muscles causing vasoconstriction, while ETB is located in the vascular smooth muscles, also causing vasoconstriction, but is also located on endothelial cells, resulting in activation of NO and PGI2, leading to vasodilation. In PAH patients, there is more expression of ETA and ETB in smooth muscles, causing vasoconstriction [5, 13].
Therapies for PAH have progressed in the last two decades, with more medication targeting different pathways and resulting in more effective outcomes. Based on the current literature, a number of variables influence the prognosis of the disease, allowing us to risk-stratify patients into low, intermediate, and high mortality risk. The main goal in treating PAH patients now is to get patients to a low-risk classification (Table 2) [5, 14, 15].
Available treatments include phosphodiesterase-5 inhibitors (PDE5Is), prostacyclin analogs, prostacyclin receptor agonists, soluble guanylate cyclase stimulators (sGCs), and endothelin receptor antagonists (ERAs) (Fig. 1) . In this paper, we discuss current and novel drugs for treating PAH. Advances in science will help to discover pathways involved in the development of PAH, and targeting those in the next era in treating PAH (Fig. 2) .
3.1 Current Therapies
Perhaps the most widely prescribed drug in PAH is the PDE5I, including sildenafil and tadalafil. This works on the NO pathway, resulting in vasodilation and antiproliferative effects. The SUPER trial, a randomized, placebo-controlled trial, included 278 PAH patients assigned to either placebo or different doses of sildenafil three times daily. Functional class, mean pulmonary artery pressure, and PVR improved after 12 weeks of the trial in the sildenafil arm. Tadalafil was US FDA-approved in 2009 and has a longer half-life, therefore it can be prescribed once daily. The PHIRST trial was a double-blind, randomized, placebo-controlled trial that included 405 PAH patients. In 16 weeks, 40 mg of tadalafil improved exercise capacity and reduced time to clinical worsening in patients who were not receiving treatment or patients taking background bosentan [17, 18]. Riociguat, a sGC, is another agent that targets the NO pathway. The CHEST-1 trial, which included 261 patients, was a phase III, randomized, double-blinded trial. After 16 weeks, riociguat was found to improve functional capacity and PVR . A subsequent non-blinded study suggested that switching to riociguat from a PDE5I benefited patients with functional class III receiving background ERA, although there was no improvement in brain natriuretic peptide (BNP) .
FDA-approved ERAs for PAH include bosentan, ambrisentan, and macitentan. Thirty-two patients with functional class III PAH were randomized to receive bosentan or a placebo in a double-blind, randomized, placebo-controlled trial. Following 12 weeks of follow-up, the bosentan group showed improvement in 6-min walk distance (6MWD) . As the EARLY trial demonstrated, the benefit was also seen in PAH patients with functional class II . The ERA class also includes ambrisentan. Following a 12-week trial where patients were randomized to either ambrisentan or placebo, ambrisentan improved 6MWD, time to clinical worsening, and functional class . Macitentan is another FDA-approved ERA drug. Patients with PAH were randomly assigned to either macitentan 3 or 10 mg or a placebo in the SERAPHIN trial. Primary endpoints were death, clinical worsening, initiation of intravenous or subcutaneous prostanoids, atrial septostomy, and lung transplantation. A primary endpoint occurred in 46.4% of placebo patients, 38.0% of patients in the macitentan 3 mg group, and 31.4% of patients in the macitentan 10 mg group. The hazard ratio for the macitentan 3 mg dose compared with placebo was 0.70, with a p value of 0.01, and the hazard ratio for the macitentan 10 mg dose compared with placebo was 0.55, with a p value of < 0.001. The study was positive regardless of whether the patient was receiving prior therapy for PAH .
Prostanoid drugs were the first available PAH-specific therapy, targeting the prostacyclin pathway. Intravenous, subcutaneous, and inhaled forms of prostanoids have all not only had their benefits but also their challenges. Intravenous epoprostenol was the first agent to be studied and approved for PAH, having demonstrated improved symptoms and decreased mortality. Treprostinil has been shown to improve 6MWD through intravenous, subcutaneous, and inhaled forms. Oral treprostinil went on to become the first oral prostanoid to be FDA-approved, after FREEDOM M and FREEDOM-EV showed that oral treprostinil improved 6MWD as monotherapy and reduced time to clinical worsening when used in combination with either an ERA or PDE5I [25,26,27]. Selexipag is a prostacyclin receptor agonist that was studied in the GRIPHON trial. In this study, a composite of death from any cause or complications related to PAH occurred in 41.6% and 27.0% of those patients in the placebo group versus those in the selexipag group .
Treatment of PAH has progressed in recent years to include combination therapy that targets the above pathways. Trials such as AMBITION, GRIPHON, and FREEDOM-EV have demonstrated the effectiveness of dual combination therapy in PAH patients. How and when to start triple therapy is less well described or studied.
3.2 Novel Therapies
3.2.1 Transforming Growth Factor-β Pathway
BMPs are part of the transforming growth factor (TGF)-β family; unopposed TGF-β signals happen when we have a loss of function of the BMPR2 genes, which is essential in regulating vascular cell apoptosis and maintaining normal function of the endothelium. When BMPR2 is suppressed, there is unopposed signaling of TGF-β, resulting in proliferation of the vascular cells and remodeling [29, 30]. Sotatercept is a novel drug that works on the BMPR2 gene and the TGF-β pathway. By working as a trap ligand of the TGF-β pathway, it helps to suppress TGF-β and enhances the BMPR2. In the phase II PULSAR trial, PVR was reduced by 34% in patients treated with sotatercept when compared with placebo. 6MWD and NT-pro-BNP were also reduced. Thirty-seven percent of patients were receiving background parenteral treatment and 56% were receiving triple therapy. The STELLAR trial, a phase III, multicenter, double-blind trial, included 323 patients who were receiving stable background therapy. Patients were randomized to receive sotatercept or placebo. The primary endpoint was change in 6MWD at 24 weeks. At 24 weeks, the difference in change in the 6MWD between the sotatercept and placebo groups was + 40.8 m (95% confidence interval [CI] 27.5–54.1; p < 0.001) in favor of sotatercept. Sotatercept also had a significant difference in time to first death or non-fatal clinical worsening events. At week 24, the sotatercept group showed significant improvement in NT-proBNP levels, functional class, and PVR. Furthermore, sotatercept had more adverse events, such as an increase in hemoglobin, thrombocytopenia, telangiectasia, epistaxis and dizziness, when compared with the placebo group [31,32,33,34].
3.2.2 Platelet-Derived Growth Factor Pathway
Platelet-derived growth factor (PDGF) is reported to have a role in PAH. PDGF acts through transmembrane tyrosine kinase receptors, and when the PDGF is overexpressed, it leads to proliferation of the pulmonary artery smooth muscles. It has been reported that patients with PAH have increased signaling of the PDGF pathway. Imatinib, a tyrosine kinase inhibitor, has been studied in PAH [29, 35, 36]. In a phase II, randomized, double-blinded trial that included 59 patients with PAH, with a primary endpoint of change in 6MWD and safety and tolerability, resulted in no significant change in 6MWD but significant reduction of PVR in the treatment arm. This study suggested that imatinib was probably safe and well tolerated in PAH patients and provided a reference for further studies . The IMPRES trial was a phase III trial aiming to assess the effect of imatinib in PAH patients; 202 patients were included, with PVR ≥ 10 Wood units and receiving two or more therapies for PAH. The primary endpoint was change in 6MWD. After 24 weeks of follow-up, oral imatinib significantly helped to reduce 6MWD and PVR. However, the study showed a 44% incidence of serious adverse events, including a number of patients having subdural hematoma, and a high rate of discontinuations; thus far, imatinib has not been FDA-approved for PAH treatment . A phase III trial (IMPAHCT, NCT05036135) that is currently recruiting patients is studying dry powder imatinib in patients with PAH. This study is interesting because imatinib will likely not have the systemic adverse effects that were observed in the IMPRES study. The primary endpoint of this trial was to establish a dose for phase III. The primary endpoint of the phase III part of the trial is the change in 6MWD at 24 weeks. Alternative formulations of imatinib are also under study, such as an enteric-coated version .
Inhaled seralutinib is a unique small molecule inhibitor of the PDGF receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. Inhaled seralutinib is also in clinical development and is being studied in PAH . The phase II TORREY trial showed that patients treated with seralutinib had a statistically significant placebo-corrected improvement in PVR of 14.3%. A phase III study is being planned.
3.2.3 Prostacyclin Pathway
Ralinepag is an immediate-release oral drug acting as a non-prostanoid prostacyclin receptor agonist that acts on the prostacyclin pathway, similar to selexipag but with a longer half-life. Ralinepag was studied in a phase II trial of 61 patients. The study showed promising findings of significant improvement in 6MWD and significant reduction of PVR in patients receiving monotherapy or dual therapy compared with placebo [31, 41, 42]. Several trials are currently underway with ralinepag. The ADVANCE OUTCOMES trial (NCT03626688) is a phase III trial that is currently recruiting, and is intending to recruit 700 patients. This is a multicenter, randomized, double-blinded trial with a primary endpoint of time to clinical worsening. Patients will be randomized to either placebo or ralinepag in addition to standard of care.
3.2.4 Other Pathways
Udenafil is a long-acting PDE5I that has a favorable safety profile. In a phase II trial, patients were randomized to three groups—placebo, udenafil 50 mg or udenafil 100 mg. Hemodynamics were monitored for 4 h after drug administration. The results showed a reduction in mPAP for both doses and a reduction in PVR, with statistical significance in the 50 mg arm . Chang et al. studied udenafil in a 16-week, randomized, double-blinded, phase IIb trial. Sixty-three patients were randomized to either placebo or udenafil 50 mg. Patients taking udenafil significantly improved in 6MWD, and udenafil had a good safety profile .
Serotonin pathways have been implicated in the pathophysiology of PAH. Serotonin has been found to promote pulmonary vascular smooth muscle proliferation. Rodatristat ethyl works on the serotonin pathway as a tryptophan hydroxylase 1 inhibitor, which in turn reduces the release of serotonin . The ELEVATE 2 trial (NCT04712669) is a phase II, randomized, double-blind, placebo-controlled trial that is currently recruiting. The study’s goal is to include 90 patients and to randomize to either rodatristat ethyl 300 mg twice daily or rodatristat ethyl 600 mg twice daily compared with placebo, in addition to standard of care in both arms. The primary outcome is the change in PVR at 24 weeks.
The vasoactive intestinal peptide (VIP) analog pemziviptadil (PB1046) has been studied in PAH, however the studies were terminated due to poor recruitment during the coronavirus disease 2019 (COVID-19) pandemic .
The optimum dose of macitentan is currently under investigation. In the phase III UNISUS trial (NCT04273945), 900 patients will be randomized to receive either 10 mg once daily or a matching placebo of macitentan 37.5 mg for 4 weeks (up-titration) and a matching placebo of macitentan 75 mg after that. The primary endpoint is time to first morbidity and mortality event, defined as all-cause death, PAH-related hospitalization, or PAH disease progression .
A combination pill has not been previously studied in PAH. A phase III trial (NCT03904693) is planned and is expected to be a randomized, double-blind study with a target of 187 PAH patients looking at a combined pill comprising of macitentan and ambrisentan compared with both drugs being taken individually. The primary endpoint is changes in PVR at 16 weeks.
Other drugs such as metformin are thought to be helpful in PAH patients. Insulin resistance is thought to be a risk factor for PAH. Metformin affects the production of NO and ROS and thus helps prevent proliferation and remodeling. However, the studies are in the recruitment phase.
Despite advances in the treatments of PAH, the mortality rate remains unacceptably high. Currently, three pathways are effectively targeted. However, the emergence of a number of new targets currently in active clinical trials is very encouraging and suggests improved outcomes for patients with PAH in the near future.
Alamri AK, Ma CL, Ryan JJ. Left heart disease-related pulmonary hypertension. Cardiol Clin. 2022;40(1):69–76.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.
Sommer N, Ghofrani HA, Pak O, Bonnet S, Provencher S, Sitbon O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178(1):6–30.
Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017;36(9):957–67.
Lan NS, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases. 2018;6(2):38.
Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98(24):1805–11.
Weatherald J, Boucly A, Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr Opin Pulm Med. 2018;24(5):407–15.
Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159–65.
Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25S):D4–12.
Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214–21.
Zhao Y-Y, Zhao YD, Mirza MK, Huang JH, Potula H-HS, Vogel SM, et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Investig. 2009;119(7):2009–18.
Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–5.
Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med. 2012;52(9):1970–86.
Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(38):3618–731.
Qaiser KN, Tonelli AR. Novel treatment pathways in pulmonary arterial hypertension. Methodist Debakey Cardiovasc J. 2021;17(2):106.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.
Ghofrani H-A, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–29.
Hoeper MM, Simonneau G, Corris PA, Ghofrani H-A, Klinger JR, Langleben D, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425.
Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358(9288):1119–23.
Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–100.
Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.
Jing Z-C, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–33.
Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383–90.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–17.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Hemnes AR, Humbert M. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur Respir Rev. 2017;26(146): 170093.
Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci. 2017;74(16):2979–95.
Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. J Investig Med. 2021;69(7):1270–80.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204–15.
MERCK. Merck announces positive top-line results from pivotal phase 3 STELLAR trial evaluating sotatercept for the treatment of adults with pulmonary arterial hypertension (PAH). Merck; 2022.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. https://doi.org/10.1056/NEJMoa2213558. Epub 6 Mar 2023.
Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189–208.
Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(1):81–8.
Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171–7.
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–38.
Tenax Therapeutics. Clinical development. The Impres Trial of imatinib as a treatment of PAH. WHO Group 1: pulmonary arterial hypertension (PAH). 2023.
Galkin A, Sitapara R, Clemons B, Garcia E, Kennedy M, Guimond D, et al. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur Respir J. 2022;60(6):2102356.
McLaughlin V, Channick R, Walsh B, Keating M, Gilder K, Cabell C, et al. Study design of the phase 3 advance program evaluating time-to-clinical events and exercise capacity in patients with pulmonary arterial hypertension treated with ralinepag. In: C51 closer to the heart: update on approved therapies for PAH. American Thoracic Society; 2019. p. A5074-A.
Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019;54(4):1901030.
Chang S-A, Kim H-K, Chang HJ, Kim D-K. Acute hemodynamic changes after single administration of udenafil in pulmonary arterial hypertension: a phase IIa study. Korean Circ J. 2019;49(4):353–60.
Chang H-J, Song S, Chang S-A, Kim H-K, Jung H-O, Choi J-H, et al. Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIb clinical trial. Clin Ther. 2019;41(8):1499–507.
Lazarus HM, Denning J, Wring S, Palacios M, Hoffman S, Crizer K, et al. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). Pulm Circ. 2022;12(2): e12088.
McLaughlin V, Hoeper M, Tamura Y, Backer A, Boyanova N, Kracker H, et al. UNISUS study design: a phase 3 superiority study comparing the efficacy, safety, and tolerability of macitentan 75 mg vs macitentan 10 mg in patients with pulmonary arterial hypertension (PAH). Eur Heart J. 2022;43(Suppl 2):ehac544.1929.
Dr. Ryan and his research are supported by the Gordon family and the Reagan Foundation.
John J. Ryan, and his research, is supported by funding from the Gordon family and the Reagan Corporation.
Conflict of interest
Ayedh K. Alamri, Christy L. Ma, and John J. Ryan declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Consent to participate
Consent for publication
All authors contributed equally to the conceptualization of this article, review of the literature, writing of this article, and final revision.
About this article
Cite this article
Alamri, A.K., Ma, C.L. & Ryan, J.J. Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?. Drugs 83, 577–585 (2023). https://doi.org/10.1007/s40265-023-01862-z